They would be monitored for the next three or four years to assess their tolerance levels, Clark said, adding that there was no reason why the clinical trial could not be extended to adults.
"For all our participants, a reaction could lead to life-threatening anaphylactic shock. It's not a permanent cure, but as long as they go on taking a daily dose they should maintain their tolerance," he said.
About one in 50 children in Britain are allergic to peanuts, and ingesting them can cause difficulty in breathing, cardiac arrest and even death.
The trial was sponsored by the Evelyn Trust, a Cambridge charity supporting medical research.
Source-AFP
SRM